Receptor-based pharmacophores for serotonin 5-HT7R antagonists - Implications to selectivity

Journal of Medicinal Chemistry

Volumn 49, Issue 23, 2006, Pages 6732-6741

  Kołaczkowski, Marcin ^a,b   Nowak, Mateusz ^a   Pawłowski, Maciej ^b   Bojarski, Andrzej J ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; 3,N DIMETHYL N [1 METHYL 3 (4 METHYL 1 PIPERIDINYL)PROPYL]BENZENESULFONAMIDE; AMESERGIDE; AMITRIPTYLINE; APORPHINE DERIVATIVE; BETA CARBOLINE DERIVATIVE; CLOZAPINE; DR 4004; DR 4365; DR 4446; ERGOLINE DERIVATIVE; ERGOTAMINE; G PROTEIN COUPLED RECEPTOR; LIGAND; MAPROTILINE; METERGOLINE; MIANSERIN; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; RADIOLIGAND; SB 258741; SB 656104; SB 691673; SEROTONIN; SEROTONIN 7 RECEPTOR; SEROTONIN ANTAGONIST; SULFONAMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; COMPLEX FORMATION; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; HUMAN CELL; HYDROGEN BOND; NONHUMAN; PHARMACOPHORE; SEROTONINERGIC SYSTEM;

ANIMALS; BINDING SITES; LIGANDS; MODELS, MOLECULAR; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 33750970572     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060300c     Document Type: Article

References (65)

1. Ruat, M.; Traiffort, E.; Leurs, R.; Tardivel-Lacombe, J.; Diaz, J.; Arrang, J. M.; Schwartz, J. C. Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 8547-8551.
2. Bard, J. A.; Zgombick, J.; Adham, N.; Vaysse, P.; Branchek, T. A.; Weinshank, R. L. Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J. Biol. Chem. 1993, 268, 23422-23426.
3. Lovenberg, T. W.; Baron, B. M.; de Lecea, L.; Miller, J. D.; Prosser, R. A.; Rea, M. A.; Foye, P. E.; Racke, M.; Slone, A. L.; Siegel, B. W.; et al. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron 1993. 11, 449-458.
4. Plassat, J. L.; Amlaiky, N.; Hen, R. Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. Mol. Pharmacol. 1993, 44, 229-236.
5. Shen, Y.; Monsma, F. J., Jr.; Metcalf, M. A.; Jose, P. A.; Hamblin, M. W.; Sibley, D. R. Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J. Biol. Chem. 1993, 268, 18200-18204.
6. Hagan, J. J.; Price, G. W.; Jeffrey, P.; Deeks, N. J.; Stean, T.; Piper, D.; Smith, M. I.; Upton, N.; Medhurst, A. D.; Middlemiss, D. N.; Riley, G. J.; Lovell, P. J.; Bromidge, S. M.; Thomas, D. R. Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist. Br. J. Pharmacol. 2000, 130, 539-548.
7. Hedlund, P. B.; Danielson, P. E.; Thomas, E. A.; Slanina, K.; Carson, M. J.; Sutcliffe, J. G. No hypothermic response to serotonin in 5-HT7 receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 1375-1380.
8. Guscott, M. R.; Egan, E.; Cook, G. P.; Stanton, J. A.; Beer, M. S.; Rosahl, T. W.; Hartmann, S.; Kulagowski, J.; McAllister, G.; Fone, K. C.; Hutson, P. H. The hypothermic effect of 5-CT in mice is mediated through the 5-HT7 receptor. Neuropharmacology 2003, 44, 1031-1037.
9. Thomas, D. R.; Melotto, S.; Massagrande, M.; Gribble, A. D.; Jeffrey, P.; Stevens, A. J.; Deeks, N. J.; Eddershaw, P. J.; Fenwick, S. H.; Riley, G.; Stean, T.; Scott, C. M.; Hill, M. J.; Middlemiss, D. N.; Hagan, J. J.; Price, G. W.; Forbes, I. T. SB-656104-A, a novel selective 5-HT(7) receptor antagonist, modulates REM sleep in rats. Br. J. Pharmacol. 2003, 139, 705-714.
10. Duncan, M. J.; Grear, K. E.; Hoskins, M. A. Aging and SB-269970-A, a selective 5-HT7 receptor antagonist, attenuate circadian phase advances induced by microinjections of serotonergic drugs in the hamster dorsal raphe nucleus. Brain Res. 2004, 1008, 40-48.
11. Duncan, M. J.; Davis, V. A. Cyclic AMP mediates circadian phase shifts induced by microinjection of serotonergic drugs in the hamster dorsal raphe nucleus. Brain Res. 2005, 1058, 10-16.
12. Meneses, A.; Terron, J. A. Role of 5-HT(1A) and 5-HT(7) receptors in the facilitatory response induced by 8-OH-DPAT on learning consolidation. Behav. Brain Res. 2001, 121, 21-28.
13. Meneses, A. Effects of the 5-HT7 receptor antagonists SB-269970 and DR 4004 in autoshaping Pavlovian/instrumental learning task. Behav. Brain Res. 2004, 155, 275-282.
14. Perez-Garcia, G. S.; Meneses, A. Effects of the potential 5-HT7 receptor agonist AS 19 in an autoshaping learning task. Behav. Brain Res. 2005, 163, 136-140.
15. Perez-Garcia, G.; Gonzalez-Espinosa, C.; Meneses, A. An mRNA expression analysis of stimulation and blockade of 5-HT(7) receptors during memory consolidation. Behav. Brain Res. 2006, 169, 83-92.
16. Bourson, A.; Kapps, V.; Zwingelstein, C.; Rudler, A.; Boess, F. G.; Sleight, A. J. Correlation between 5-HT7 receptor affinity and protection against sound-induced seizures in DBA/2J mice. Naunyn-Schmiedeberg's Arch. Pharmacol. 1997, 356, 820-826.
17. Graf, M.; Jakus, R.; Kantor, S.; Levay, G.; Bagdy, G. Selective 5-HT1A and 5-HT7 antagonists decrease epileptic activity in the WAG/Rij rat model of absence epilepsy. Neurosci. Lett. 2004, 359, 45-48.
18. Mahe, C.; Loetscher, E.; Dev, K. K.; Bobirnac, I.; Otten, U.; Schoeffter, P. Serotonin 5-HT7 receptors coupled to induction of interleukin-6 in human microglial MC-3 cells. Neuropharmacology 2005, 49, 40-47.
19. Terron, J. A.; Falcon-Neri, A. Pharmacological evidence for the 5-HT7 receptor mediating smooth muscle relaxation in canine cerebral arteries. Br. J. Pharmacol. 1999, 127, 609-616.
20. Hedlund, P. B.; Sutcliffe, J. G. Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol. Sci. 2004, 25, 481-486.
21. Thomas, D. R.; Hagan, J. J. 5-HT7 receptors. Curr. Drug Targets: CNS Neurol. Disord. 2004, 3, 81-90.
22. East, S. Z.; Burnet, P. W.; Kerwin, R. W.; Harrison, P. J. An RT-PCR study of 5-HT(6) and 5-HT(7) receptor mRNAs in the hippocampal formation and prefrontal cortex in schizophrenia. Schizophr. Res. 2002, 57, 15-26.
23. Pouzet, B.; Didriksen, M.; Arnt, J. Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia. Pharmacol. Biochem. Behav. 2002, 71, 655-665.
24. Ikeda, M.; Iwata, N.; Kitajima, T.; Suzuki, T.; Yamanouchi, Y.; Kinoshita, Y.; Ozaki, N. Positive association of the serotonin 5-HT(7) receptor gene with schizophrenia in a Japanese population. Neuropsychopharmacology 2006, 31, 866-871.
25. Guscott, M.; Bristow, L. J.; Hadingham, K.; Rosahl, T. W.; Beer, M. S.; Stanton, J. A.; Bromidge, F.; Owens, A. P.; Huscroft, I.; Myers, J.; Rupniak, N. M.; Patel, S.; Whiting, P. J.; Hutson, P. H.; Fone, K. C.; Biello, S. M.; Kulagowski, J. J.; McAllister, G. Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression. Neuropharmacology 2005, 48, 492-502.
26. Hedlund, P. B.; Huitron-Resendiz, S.; Henriksen, S. J.; Sutcliffe, J. G. 5-HT(7) receptor inhibition and inactivation induce antidepressant like behavior and sleep pattern. Biol. Psychiatry 2005, 58, 831-837.
27. To, Z. P.; Bonhaus, D. W.; Eglen, R. M.; Jakeman, L. B. Characterization and distribution of putative 5-ht7 receptors in guinea-pig brain. Br. J. Pharmacol. 1995, 115, 107-116.
28. Gushing, D. J.; Zgombick, J. M.; Nelson, D. L.; Cohen, M. L. LY215840, a high-affinity 5-HT7 receptor ligand, blocks serotonin-induced relaxation in canine coronary artery. J. Pharmacol. Exp. Ther. 1996, 277, 1560-1566.
29. Linnanen, T.; Brisander, M.; Mohell, N.; Johansson, A. M. Serotonergic and dopaminergic activities of rigidified (R)-aporphine derivatives. Bioorg. Med. Chem. Lett. 2001, 11, 367-370.
30. Linnanen, T.; Brisander, M.; Unelius, L.; Rosqvist, S.; Nordvall, G.; Hacksell, U.; Johansson, A. M. Atropisomeric derivatives of 2′,6′- disubstituted (R)-II-phenylaporphine: selective serotonin 5-HT(7) receptor antagonists. J. Med. Chem. 2001, 44, 1337-1340.
31. Linnanen, T.; Brisander, M.; Unelius, L.; Sundholm, G.; Hacksell, U.; Johansson, A. M. Derivatives of (R)-I,II-methyleneaporphine: Synthesis, structure, and interactions with G-protein coupled receptors. J. Med. Chem. 2000, 43, 1339-1349.
32. Lucchelli, A.; Santagostino-Barbone, M. G.; D'Agostino, G.; Masoero, E.; Tonini, M. The interaction of antidepressant drugs with enteric 5-HT7 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, 362, 284-289.
33. Kikuchi, C.; Ando, T.; Watanabe, T.; Nagaso, H.; Okuno, M.; Hiranuma, T.; Koyama, M. 2a-[4-(Tetrahydropyridoindol-2-yl)butyl]-tetrahydrobenzindole derivatives: New selective antagonists of the 5-hydroxytryptamine7 receptor. J. Med. Chem. 2002, 45, 2197-2206.
34. Kikuchi, C.; Suzuki, H.; Hiranuma, T.; Koyama, M. New tetrahydrobenzindoles as potent and selective 5-HT(7) antagonists with increased in vitro metabolic stability. Bioorg. Med. Chem. Lett. 2003, 13, 61-64.
35. Kikuchi, C.; Nagaso, H.; Hiranuma, T.; Koyama, M. Tetrahydrobenzindoles: selective antagonists of the 5-HT7 receptor. J. Med. Chem. 1999, 42, 533-535.
36. Kikuchi, C.; Hiranuma, T.; Koyama, M. Tetrahydrothienopyridylbutyl- tetrahydrobenzindoles: new selective ligands of the 5-HT(7) receptor. Bioorg. Med. Chem. Lett. 2002, 12, 2549-2552.
37. Forbes, I. T.; Cooper, D. G.; Dodds, E. K.; Douglas, S. E.; Gribble, A. D.; Ife, R. J.; Lightfoot, A. P.; Meeson, M.; Campbell, L. P.; Coleman, T.; Riley, G. J.; Thomas, D. R. Identification of a novel series of selective 5-HT(7) receptor antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 1055-1058.
38. Leopoldo, M.; Berardi, F.; Colabufo, N. A.; Contino, M.; Lacivita, E.; Niso, M.; Perrone, R.; Tortorella, V. Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents. J. Med. Chem. 2004, 47, 6616-6624.
39. Leopoldo, M.; Berardi, F.; Colabufo, N. A.; Contino, M.; Lacivita, E.; Perrone, R.; Tortorella, V. Studies on 1-arylpiperazine derivatives with affinity for rat 5-HT7 and 5-HT1A receptors. J. Pharm. Pharmacol. 2004, 56, 247-255.
40. Perrone, R.; Berardi, F.; Colabufo, N. A.; Lacivita, E.; Leopoldo, M.; Tortorella, V. Synthesis and structure-affinity relationships of 1-[ω-(4-aryl-1-piperazinyl)alkyl]-1-aryl ketones as 5-HT(7) receptor ligands. J. Med. Chem. 2003, 46, 646-649.
41. Forbes, I. T.; Dabbs, S.; Duckworth, D. M.; Jennings, A. J.; King, F. D.; Lovell, P. J.; Brown, A. M.; Collin, L.; Hagan, J. J.; Middlemiss, D. N.; Riley, G. J.; Thomas, D. R.; Upton, N. (R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl- piperidin-1-yl)propyl]benzenesulfonamide: The first selective 5-HT7 receptor antagonist. J. Med. Chem. 1998, 41, 655-657.
42. Lovell, P. J.; Bromidge, S. M.; Dabbs, S.; Duckworth, D. M.; Forbes, I. T.; Jennings, A. J.; King, F. D.; Middlemiss, D. N.; Rahman, S. K.; Saunders, D. V.; Collin, L. L.; Hagan, J. J.; Riley, G. J.; Thomas, D. R. A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-Methylpiperidin-1-yl)ethyl) pyrrolidine-1-sulfonyl)phenol (SB-269970). J. Med. Chem. 2000, 43, 342-345.
43. Forbes, I. T.; Douglas, S.; Gribble, A. D.; Ife, R. J.; Lightfoot, A. P.; Garner, A. E.; Riley, G. J.; Jeffrey, P.; Stevens, A. J.; Stean, T. O.; Thomas, D. R. SB-656104-A: a novel 5-HT(7) receptor antagonist with improved in vivo properties. Bioorg. Med. Chem. Lett. 2002, 12, 3341-3344.
44. Denhart, D. J.; Purandare, A. V.; Catt, J. D.; King, H. D.; Gao, A.; Deskus, J. A.; Poss, M. A.; Stark, A. D.; Torrente, J. R.; Johnson, G.; Mattson, R. J. Diaminopyrimidine and diaminopyridine 5-HT7 ligands. Bioorg. Med. Chem. Lett. 2004, 14, 4249-4252.
45. Mattson, R. J.; Denhart, D. J.; Catt, J. D.; Dee, M. F.; Deskus, J. A.; Ditta, J. L.; Epperson, J.; Dalton, K. H.; Gao, A.; Poss, M. A.; Purandare, A.; Tortolani, D.; Zhao, Y.; Yang, H.; Yeola, S.; Palmer, J.; Torrente, J.; Stark, A.; Johnson, G. Aminotriazine 5-HT7 antagonists. Bioorg. Med. Chem. Lett. 2004, 14, 4245-4248.
46. Holmberg, P.; Sohn, D.; Leideborg, R.; Caldirola, P.; Zlatoidsky, P.; Hanson, S.; Mohell, N.; Rosqvist, S.; Nordvall, G.; Johansson, A. M.; Johansson, R. Novel 2-aminotetralin and 3-aminochroman derivatives as selective serotonin 5-HT7 receptor agonists and antagonists. J. Med. Chem. 2004, 47, 3927-3930.
47. Holmberg, P.; Tedenborg, L.; Rosqvist, S.; Johansson, A. M. Novel 3-aminochromans as potential pharmacological tools for the serotonin 5-HT(7) receptor. Bioorg. Med. Chem. Lett. 2005, 15, 747-750.
48. Lopez-Rodriguez, M. L.; Porras, E.; Benhamu, B.; Ramos, J. A.; Morcillo, M. J.; Lavandera, J. L. First pharmacophoric hypothesis for 5-HT7 antagonism. Bioorg. Med. Chem. Lett. 2000, 10, 1097-1100.
49. Lopez-Rodriguez, M. L.; Porras, E.; Morcillo, M. J.; Benhamu, B.; Soto, L. J.; Lavandera, J. L.; Ramos, J. A.; Olivella, M.; Campillo, M.; Pardo, L. Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives. J. Med. Chem. 2003, 46, 5638-5650.
50. Vermeulen, E. S.; van Smeden, M.; Schmidt, A. W.; Sprouse, J. S.; Wikstrom, H. V.; Grol, C. J. Novel 5-HT7 receptor inverse agonists. Synthesis and molecular modeling of arylpiperazine- and 1,2,3,4-tetrahydroisoquinoline- based arylsulfonamides. J. Med. Chem. 2004, 47, 5451-5466.
51. Nowak, M.; Kolaczkowski, M.; Pawlowski, M.; Bojarski, A. J. Homology modeling of the serotonin 5-HT1A receptor using automated docking of bioactive compounds with defined geometry. J. Med. Chem. 2006, 49, 205-214.
52. Leopolde, M. Serotonin(7) receptors (5-HT(7)Rs) and their ligands. Curr. Med. Chem. 2004, 11, 629-661.
53. Ballesteros, J. A.; Weinstein, H. Integrated methods for modeling G-protein coupled receptors. Methods Neurosci. 1996, 25, 366-428.
54. Sali, A.; Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993, 234, 779-815.
55. Evers, A.; Klebe, G. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. J. Med. Chem. 2004, 47, 5381-5392.
56. Evers, A.; Klabunde, T. Structure-based drug discovery using GPCR homology modeling: Successful virtual screening for antagonists of the alpha1A adrenergic receptor. J. Med. Chem. 2005, 48, 1088-1097.
57. Varady, J.; Wu, X.; Fang, X.; Min, J.; Hu, Z.; Levant, B.; Wang, S. Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: Discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. J. Med. Chem. 2003, 46, 4377-4392.
58. Lopez-Rodriguez, M. L.; Vicente, B.; Deupi, X.; Barrondo, S.; Olivella, M.; Morcillo, M. J.; Behamu, B.; Ballesteros, J. A.; Salles, J.; Pardo, L. Design, synthesis and pharmacological evaluation of 5-hydroxytryptamine(la) receptor ligands to explore the three-dimensional structure of the receptor. Mol. Pharmacol. 2002, 62, 15-21.
59. Evers, A.; Gohlke, H.; Klebe, G. Ligand-supported homology modelling of protein binding-sites using knowledge-based potentials. J. Mol. Biol. 2003, 334, 327-345.
60. Seeber, M.; De Benedetti, P. G.; Fanelli, F. Molecular dynamics simulations of the ligand-induced chemical information transfer in the 5-HT(1A) receptor. J. Chem. Inf. Comput. Sci. 2003, 43, 1520-1531.
61. Sealfon, S. C.; Chi, L.; Ebersole, B. J.; Rodic, V.; Zhang, D.; Ballesteros, J. A.; Weinstein, H. Related contribution of specific helix 2 and 7 residues to conformational activation of the serotonin 5-HT2A receptor. J. Biol. Chem. 1995, 270, 16683-16688.
62. Zhou, W.; Flanagan, C.; Ballesteros, J. A.; Konvicka, K.; Davidson, J. S.; Weinstein, H.; Millar, R. P.; Sealfon, S. C. A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor. Mol. Pharmacol. 1994, 45, 165-170.
63. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast, flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 267, 470-489.
64. Strader, C. D.; Sigal, I. S.; Candelore, M. R.; Rands, E.; Hill, W. S.; Dixon, R. A. Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. J. Biol. Chem. 1988, 263, 10267-10271.
65. 1A receptor affinity in the group of long-chain arylpiperazine ligands. Bioorg. Med. Chem. Lett. 2004, 14, 5863-5866.